I completely agree that this is political noisemaking. Investors who fear patents being invalidated are out to lunch.
On top of it, the lawmakers generally pick poor targets. GILD and MDVN's drugs are exactly what the US healthcare system needs: efficacious (one a game changer) small molecule drugs that will eventually be available as cheap generics.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.